How does HAART lead to the resolution of Kaposi's sarcoma?

Open Access
Publisher Website
Google Scholar
Abstract
As highly active antiretroviral therapy (HAART) is available for less than one million individuals worldwide, Kaposi’s sarcoma (KS) remains a common complication of infection with the human immunodeficiency virus (HIV). Use of HAART has reduced the incidence of KS and, in affected individuals, HAART alone can lead to KS resolution. Possible mechanisms include general improvements in immune function including the specific generation of anti-KS responses, the inhibition of HIV-1 cofactors that are thought to be important in tumour development and inhibitory effects on angiogenic growth factors and cytokines that promote KS formation. The relative contributions of these mechanisms will be discussed.

This publication has 0 references indexed in Scilit: